After Ebola success, Regeneron turns antibody capabilities against 2019-nCoV 

Regeneron's offices (Regeneron)

Regeneron has teamed up with the U.S. Department of Health and Human Services (HHS) to develop a treatment for the coronavirus outbreak. The alliance will leverage Regeneron antibody technology that gave rise to an effective treatment for the Ebola virus. 

Through the project, Regeneron and the HHS’ Office of the Assistant Secretary for Preparedness and Response (ASPR) aim to develop multiple monoclonal antibodies that, when given as monotherapies or in combination, treat the 2019-nCoV coronavirus. The plan is to develop antibodies that bind to viral proteins and, in doing so, stop the pathogen from readily infecting human cells.

Regeneron has previously applied its antibody discovery capabilities to pathogens including Ebola and Middle East respiratory syndrome coronavirus (MERS-CoV). The Ebola medicine emerged from a four-therapy clinical trial as one of the preferred treatments for the virus.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The 2019-nCoV collaboration unveiled this week is an expansion of an existing relationship between Regeneron and HHS, which teamed up in 2017 to work on antibodies against up to 10 pathogens. 

Rick Bright, deputy assistant secretary for preparedness and response and director of the Biomedical Advanced Research and Development Authority at ASPR, framed the expanded collaboration as part of the U.S. government’s efforts to protect the nation.

“Emerging infectious diseases can present serious threats to our nation's health security. Working as public-private partners like we have with Regeneron since 2014, we can move rapidly to respond to new global health threats,” Bright said in a statement. 

The HHS-Regeneron collaboration opens another front in the growing effort to develop medicines and vaccines against 2019-nCoV. Other companies including AbbVie, Gilead Sciences and Moderna are also going after the virus. Some of those projects are more advanced than Regeneron’s program, but HHS thinks its partner can move quickly, pointing to technology that truncated development of the Ebola and MERS-CoV antibodies to make its case.  

Suggested Articles

Wedding Five Prime Therapeutics’ cabiralizumab to Bristol-Myers Squibb’s checkpoint inhibitor Opdivo has proved to be a bust in pancreatic cancer.

In an SEC filing, Baxter International disclosed that it may have overstated its income over multiple years, inflating it by about $276 million.

The FDA has given Grail a green light to conduct the interventional study, and it has begun enrolling participants through the company’s R&D partners.